# A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis

> **NCT05208840** · PHASE4 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT05208840
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09-15
- **Primary completion:** 2025-01-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to deterioration of the geopolitical situation and escalation of conflict between Russia and Ukraine ML42302 study was put on hold.
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05208840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05208840, "A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05208840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*